Search
teprotumumab-trbw (Tepezza)
Indications:
- treatment of proptosis of thyroid eye disease
Contraindications:
- pregnancy*
* pregnancy prevention for 6 months following last dose of Tepezza
Dosage:
- 10 mg/kg IV initially
- follow with 20 mg/kg IV q3 weeks for 7 additional infusions
- 500mg/single-dose vial
Pharmacokinetics:
- no dosages adjustment for renal failure
Adverse effects:
- nausea, diarrhea, dysgeusia
- alopecia, hyperglycemia, hearing loss, dry skin
- muscle spasm, headache, fatigue,
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
endocrine agent
References
- FDA News Release. January 21, 2020
FDA approves first treatment for thyroid eye disease
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease
- Rothaus C
Teprotumumab for Thyroid Eye Disease.
NEJM Resident 360. Ja 22, 2020
https://resident360.nejm.org/clinical-pearls/teprotumumab-for-thyroid-eye-disease
- Strawbridge JC et al.
Google searches for thyroid eye disease after regulatory approval of
teprotumumab.
JAMA Ophthalmol 2022 Apr 28;
PMID: 35482336 PMCID: PMC9052105 (available on 2023-04-28)
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2791596
- Medscape: teprotumumab (Rx)
https://reference.medscape.com/drug/tepezza-teprotumumab-4000026